Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

Defence Therapeutics Inc., CA24463V1013

Defence Therapeutics Inc., CA24463V1013

06.10.2021 - 08:33:25

Defence Therapeutics Inc.: DEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMA

06.10.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English Company: Defence Therapeutics Inc. 1680 - 200 Burrard St V6C3L6 Vancouver

Canada E-mail: info@defencetherapeutics.com Internet: https://defencetherapeutics.com ISIN: CA24463V1013 WKN: A3CN14 Listed: Regulated Unofficial Market in Frankfurt, Stuttgart; Toronto EQS News ID: 1238582 ? End of News DGAP News Service

1238582??06.10.2021?

@ dgap.de